Lung adenocarcinoma harboring rare epidermal growth factor receptor L858R and V834L mutations treated with icotinib: A case report

BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors are widely used for the treatment of non-small-cell lung cancer with EGFR mutations. However, patients with rare, even compound EGFR mutations have different responses to EGFR-tyrosine-kinase inhibitors, which bring uncer...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhai, Shu-Sen, Yu, Hui, Gu, Tian-Tian, Li, Yan-Xia, Lei, Yan, Zhang, Hai-Yan, Zhen, Tong-Huan, Gao, Yun-Ge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479576/
https://www.ncbi.nlm.nih.gov/pubmed/32953862
http://dx.doi.org/10.12998/wjcc.v8.i17.3841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479576/
https://www.ncbi.nlm.nih.gov/pubmed/32953862
http://dx.doi.org/10.12998/wjcc.v8.i17.3841

Ejemplares similares